Company Performance Goals - Management has provided guidance for 2026, expecting revenue growth of 3.9% to 5.9% year-over-year and adjusted EPS growth of 5.9% to 8.4%, reaffirming a long-term organic revenue growth target of 3%-6% [1] Strategic Advancements - In 2025, the company completed the acquisition of Solventum's filtration and separation business and a sterile filling facility from Sanofi in New Jersey. In Q4 2025, it announced a proposed $8.9 billion acquisition of clinical data service provider Clario, aimed at enhancing biomanufacturing and localization capabilities. The market will focus on the synergies and integration effects of these acquisitions [2] Business Progress - The Life Sciences Solutions segment saw a profit increase of 7.6% in 2025, becoming a core growth engine, while the analytical instruments segment experienced an 11.2% profit decline. The company continues to launch new technology products, such as the Orbitrap Astral mass spectrometer, and has partnered with Open AI and the Chan Zuckerberg Initiative to promote the application of artificial intelligence in operations [3] Industry Conditions - According to a report by CMB International, demand from pharmaceutical and biotechnology clients is rebounding in 2025, with high single-digit revenue growth in Q4. The recovery in biotechnology financing may translate into order increases in the next 6-12 months, potentially driving revenue growth [4]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $4.2 million, a 37% increase from $3.1 million in Q1 2024, primarily driven by higher instrument consumable and service revenue [23] - Gross profit for Q1 2025 was $2.1 million, representing a gross margin of 49%, compared to $1.4 million and 44% in Q1 2024 [25] - Net loss for Q1 2025 was $19.9 million, compared to $20.7 million in Q1 2024 [27] - Free cash flow loss was approximately $12.1 million for Q1 2025, with expectations of a full-year loss in the range of $40 million to $45 million [27][28] Business Line Data and Key Metrics Changes - Product revenue for Q1 2025 was $2.9 million, including $5,000 from related party revenue, consisting of sales of proteograph instruments and consumable kits [23] - Service revenue for Q1 2025 was $1.2 million, primarily from STACK service projects, indicating strong customer interest [24] - Other revenue was $60,000 for Q1 2025, consisting of lease and shipping revenue [25] Market Data and Key Metrics Changes - Approximately 30% of total revenue comes from academic and government entities, with expectations of weakening in these segments for 2025 [30][42] - The company has not seen direct effects on its supply chain from recent tariffs, as key suppliers manufacture products in the U.S. [31] Company Strategy and Development Direction - The company aims to focus on four key growth drivers in 2025: expanding the user base, driving larger cohort studies, continuing product innovation, and enabling customers to generate actionable biological insights [34] - The partnership with Thermo Fisher Scientific to co-market the Proteograph product suite alongside their Orbitrap Astro Mass Spectrometer is expected to enhance commercial reach [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term vision despite near-term macroeconomic volatility, including tariffs and government funding challenges [6][7] - The company reiterated its full-year 2025 revenue guidance of $17 million to $18 million, representing 24% year-over-year growth at the midpoint [7][29] - Management noted that while there is cautious optimism, the macroeconomic environment remains uncertain, particularly regarding NIH funding and potential tariffs affecting customers [30][45] Other Important Information - The company ended Q1 2025 with approximately $285 million in cash, cash equivalents, and investments, which is seen as a key differentiator in the current environment [8][28] - The company continues its share repurchase program, believing there is a significant dislocation between its core value proposition and stock price [8][27] Q&A Session Summary Question: Can you walk us through the magnitude of the Discovery Life Sciences project? - The project involves a 10,000 sample study aimed at understanding potential biomarker signatures, expected to take 12 to 18 months [36][38] Question: What are the updated expectations for U.S. academic and government customers? - Academic and government customers represent about 30% of revenue, with expectations of weakening in 2025, but Q1 showed stability in revenue and instrument placement [42][44]